EMA/287464/2016

European Medicines Agency decision

P/0123/2016

of 12 May 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (EMEA-001825-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0123/2016

of 12 May 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (EMEA-001825-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Janssen-Cilag International NV on 3 July 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 April 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for darunavir / cobicistat / emtricitabine / tenofovir alafenamide, film-coated tablet, age appropriate formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for darunavir / cobicistat / emtricitabine / tenofovir alafenamide, film-coated tablet, age appropriate formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for darunavir / cobicistat / emtricitabine / tenofovir alafenamide, film-coated tablet, age appropriate formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Janssen-Cilag International NV, Turnhoutseweg 30, 2340 – Beerse, Belgium.

Done at London, 12 May 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/11385/2016
London, 1 April 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001825-PIP01-15

Scope of the application

Active substance(s):

Darunavir / cobicistat / emtricitabine / tenofovir alafenamide

Condition(s):

Treatment of human immunodeficiency virus type-1 (HIV-1) infection

Pharmaceutical form(s):

Film-coated tablet

Age appropriate formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Janssen-Cilag International NV

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International NV submitted for agreement to the European Medicines Agency on 3 July 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 11 August 2015.

Supplementary information was provided by the applicant on 4 January 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of human immunodeficiency virus (HIV-1) infection

The waiver applies to:

- the paediatric population below 12 years of age;
- film-coated tablet, oral use;

and

- the paediatric population below 6 years of age or weighing less than 25 kg;
- age appropriate formulation, oral use;

on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of human immunodeficiency virus type-1 (HIV-1) infection.

2.1.1. Indication(s) targeted by the PIP

Treatment of HIV-1 infection in paediatric subjects weighing 25 kg or more above 6 years of age.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Treatment of HIV-1 infection in paediatric subjects weighing 25 kg or more above 6 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age appropriate formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** Evaluation of the acceptability for paediatric patients between 12 to less than 18 year olds of the adult tablet darunavir (DRV) / cobicistat (COBI) 800/150-mg fixed dose combination (FDC). **Study 2** Development of age-appropriate oral formulation(s) of the D/C/F/TAF

Area	Number of measures	Description
		FDC and evaluation of acceptability for patients aged at least 6 years old weighing at least 25 kg.
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 3** *This study is included as Measure 6 (GS-US-216-0128) in the darunavir /cobicistat PIP EMEA- EMEA-001280-PIP01-12, P/0036/2013 of 27 February 2013 and subsequent modifications thereof.* Open-label, multicentre, multi-cohort, 2-part study to evaluate pharmacokinetics (PK), safety, and efficacy and confirm the dose of cobicistat-boosted atazanavir (ATV) or cobicistat (COB) -boosted darunavir (DRV) in children from 3 to less than 18 years of age with HIV-1 infection. **Study 4** *This study is included as Study 3 (GS-US-311-1269) of the emtricitabine/tenofovir alafenamide PIP EMEA-001577-PIP02-14, P/0032/2015 of 16 February 2015 and subsequent modifications thereof.* Open-label, randomised (Subset 2 only), active controlled (Subset 2 only) trial to evaluate pharmacokinetics, safety, tolerability and efficacy of emtricitabine/tenofovir alafenamide (F/TAF) fixed-dose combination (FDC) in children from 6 to less than 18 years of age with HIV-1 infection, who are virologically suppressed on an antiretroviral (ARV) regimen.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes